W Maat

Publications (3)10.13 Total impact

• Source

  Available from: Pieter A van der Velden

  Article: Episodic Src activation in uveal melanoma revealed by kinase activity profiling.

  W Maat, M el Filali, A Dirks-Mulder, G P M Luyten, N A Gruis, L Desjardins, P Boender, M J Jager, P A van der Velden
  [show abstract] [hide abstract]
  ABSTRACT: The RAS/RAF/MEK/ERK pathway is involved in the balance between melanocyte proliferation and differentiation. The same pathway is constitutively activated in cutaneous and uveal melanoma (UM) and related to tumour growth and survival. Whereas mutant BRAF and NRAS are responsible for the activation of the RAS/RAF/MEK/ERK pathway in most cutaneous melanoma, mutations in these genes are usually absent in UM. We set out to explore the RAS/RAF/MEK/ERK pathway and used mitogen-activated protein kinase profiling and tyrosine kinase arrays. We identified Src as a kinase that is associated with ERK1/2 activation in UM. However, low Src levels and reduced ERK1/2 activation in metastatic cell lines suggest that proliferation in metastases can become independent of Src and RAS/RAF/MEK/ERK signalling. Inhibition of Src led to the growth reduction of primary UM cultures and cell lines, whereas metastatic cell line growth was only slightly reduced. We identified Src as an important kinase and a potential target for treatment in primary UM. Metastasis cell lines seemed largely resistant to Src inhibition and indicate that in metastases treatment, a different approach may be required.
  British Journal of Cancer 07/2009; 101(2):312-9. · 5.04 Impact Factor
• Article: Methylation in uveal melanoma.

  P A van der Velden, W Maat
  The British journal of ophthalmology 01/2009; 93(1):132. · 2.92 Impact Factor
• Article: Retained intraocular foreign body masquerading as malignant melanoma of the iris.

  W Maat, G S Missotten, G P M Luyten, R J W de Keizer
  Albrecht von Graæes Archiv für Ophthalmologie 05/2008; 246(4):623-4. · 2.17 Impact Factor